Estrella Immunopharma, Inc.
ESLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.01 | -0.04 | 0.15 |
| FCF Yield | -1.70% | -1.19% | -1.39% | -2.04% |
| EV / EBITDA | -8.55 | -6.03 | -15.74 | -41.04 |
| Quality | ||||
| ROIC | 48.83% | 91.02% | 114.93% | -730.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.15 | 0.07 | 0.22 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -75.31% | 10.97% | 48.00% | 59.59% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | 0.24 | 0.20 | 0.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |